title: Prevention of human PC-346C prostate cancer growth in mice by a xenogeneic tissue vaccine.
abstract: Vaccination, as an approach to prostate cancer, has largely focused on immunotherapy utilizing specific molecules or allogeneic cells. Such methods are limited by the focused antigenic menu presented to the immune system and by immunotolerance to antigens recognized as "self". To examine if a xenogeneic tissue vaccine could stimulate protective immunity in a human prostate cancer cell line, a vaccine was produced by glutaraldehyde fixation of harvested PAIII prostate cancer cells tumors (GFT cell vaccine) from Lobund-Wistar rats. Immunocompetent Ncr-Foxn1<nu> mice were vaccinated with the GFT cell vaccine four times, 7 days apart. The control animals were either not vaccinated or vaccinated with media or glutaraldehyde-fixed PC346C human prostate cancer cells and adjuvant. About 8 days after the final boost, serum and spleens were harvested. The splenocytes were co-incubated with PC346C cells and then transplanted orthotopically into sygneneic immunodeficient nude mice. About 10 weeks later, the prostates were weighed and sampled for histolologic examination. The spleens were harvested from additional mice, and the splenocytes were cultured, either with or without pulsing by GFT cells, and the supernatants harvested 72 h later for cytokine analysis. Results showed that vaccination with GFT cells resulted in increased serum antibody to a PAIII cell lysate; reduced weight of the prostate/seminal vesicle complex and reduced incidence of prostate cancer in nude mice; increased splenocyte supernatant levels of TNF-alpha, IL-2, IFN-gamma and IL-12, cytokines associated with Th1 immunity; and increased splenocyte supernatant levels of IL-4 and IL-10, cytokines associated with Th2 immunity. In summary, the results suggest that use of a xenogeneic tissue vaccine can stimulate protective immunity against human prostate cancer cells.
authors.affiliation: Freimann Life Science Center, University of Notre Dame, Notre Dame, IN 46556, USA. suckow.1@nd.edu
authors.forename: Mark A
authors.initials: MA
authors.lastname: Suckow
authors.forename: Elliot D
authors.initials: ED
authors.lastname: Rosen
authors.forename: William R
authors.initials: WR
authors.lastname: Wolter
authors.forename: Valerie
authors.initials: V
authors.lastname: Sailes
authors.forename: Randy
authors.initials: R
authors.lastname: Jeffrey
authors.forename: Martin
authors.initials: M
authors.lastname: Tenniswood
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology / Q000473:pathology / Q000517:prevention & control / Q000628:therapy*; D000818:Animals; D000912:Antibodies, Neoplasm / Q000097:blood; D019496:Cancer Vaccines / Q000627:therapeutic use*; D045744:Cell Line, Tumor / Q000276:immunology; D002478:Cells, Cultured / Q000276:immunology / Q000378:metabolism; D018920:Coculture Techniques; D016207:Cytokines / Q000378:metabolism; D018450:Disease Progression; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D016233:Immunotherapy, Active; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009929:Organ Size; D011471:Prostatic Neoplasms / Q000276:immunology / Q000473:pathology / Q000517:prevention & control / Q000628:therapy*; D013154:Spleen / Q000276:immunology; D016176:T-Lymphocyte Subsets / Q000276:immunology / Q000378:metabolism; D047368:Tumor Burden; D014611:Vaccination; D023041:Xenograft Model Antitumor Assays
chemical_list: D000912:Antibodies, Neoplasm; D019496:Cancer Vaccines; D016207:Cytokines